期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Clinical Effect of Ilaprazole Enteric-Coated Tablets in Patients with Peptic Ulcer
1
作者 Fanghui Chen 《Journal of Biosciences and Medicines》 2024年第9期155-160,共6页
Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were sele... Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were selected as the study sample, and all patients were randomly and evenly divided into the study group (n = 100) and the control group (n = 100), and the serum inflammatory factors and the disappearance time of symptoms were compared. Results: After treatment, the serum inflammatory factors in the observation group were better than those in the control group, and the time of belching and burning sensation in the observation group was shorter than that in the control group, all of which were statistically significant (P Conclusion: Ilaprazole enteric-coated tablets in the treatment of peptic ulcer have a good effect and can effectively improve the symptoms of patients with clinical signs, with reference significance. 展开更多
关键词 Ilaprazole enteric-coated tablets Peptic Ulcer SYMPTOMS
下载PDF
Analysis of the Therapeutic Effect of Clopidogrel Bisulfate Tablets + Aspirin Enteric-Coated Tablets on Acute Myocardial Infarction
2
作者 Yiru Chen 《Journal of Clinical and Nursing Research》 2024年第6期290-294,共5页
Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from Janu... Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from January 2020 to December 2023,the sample source was 82 AMI patients admitted to our hospital,grouped into an observation group(n=41)and a control group(n=41)by the numerical table method.The patients in the control group were treated with aspirin enteric-coated tablets,and the patients in the observation group were treated with aspirin enteric-coated tablets combined with clopidogrel bisulfate.The clinical efficacy,coagulation indexes,and the incidence of cardiovascular adverse events between the two groups were compared.Results:The clinical efficacy of the observation group was higher than that of the control group(P<0.05);the platelet aggregation rate(PAR)of the observation group was lower than that of the con-trol group after treatment(P<0.05),and there was no significant difference in the prothrombin time(PT)and activated partial thromboplastin time(APTT)between the two groups(P>0.05).The incidence of cardiovascular adverse events in the observation group was lower than that of the control group(P<0.05).Conclusion:The treatment effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on AMI patients is remarkable.It reduces the PAR and the incidence of cardiovascular adverse events,so this treatment method should be popularized. 展开更多
关键词 Clopidogrel bisulfate Aspirin enteric-coated tablets Acute myocardial infarction
下载PDF
Gradient high performance liquid chromatography method for simultaneous determination of ilaprazole and its related impurities in commercial tablets 被引量:2
3
作者 Shang Wang Dong Zhang +3 位作者 Yingli Wang Xiaohong Liu Yan Liu Lu Xu 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2015年第2期146-151,共6页
A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was car... A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was carried out by gradient elution using an Agilent C8 column(4.6 mm×250 mm,5 mm)which was maintained at 25℃.The mobile phase composed of solvent A(methanol)and solvent B(solution consisting 0.02 mmol/l monopotassium phosphate and 0.025 mmol/l sodium hydroxide)was at a flow rate of 1.0 ml/min.The samples were detected and quantified at 237 nm using an ultraviolet absorbance detector.Calibration curves of all analytes from 0.5 to 3.5 mg/ml were good linearity(r≥0.9990)and recovery was greater than 99.5% for each analyte.The lower limit of detection(LLOD)and quantification(LOQ)of this analytical method were 10 ng/ml and 25 ng/ml for all impurities,respectively.The stress studies indicated that the degradation products could not interfere with the detection of ilaprazole and its related impurities and the assay can thus be considered stability-indicating.The method precisions were in the range of 0.41-1.21 while the instrument precisions were in the range of 0.38-0.95 in terms of peak area RSD% for all impurities,respectively.This method is considered stabilityindicating and is applicable for accurate and simultaneous measuring of the ilaprazole and its related impurities in commercial enteric-coated tablets. 展开更多
关键词 Ilaprazole enteric-coated tablets Related impurities HPLC Validation
下载PDF
Delayed-release oral mesalamine tablet mimicking a small jejunal gastrointestinal stromal tumor:A case report
4
作者 Fabio Frosio Emanuele Rausa +2 位作者 Paolo Marra Marie-Christine Boutron-Ruault Alessandro Lucianetti 《World Journal of Clinical Cases》 SCIE 2022年第19期6710-6715,共6页
BACKGROUND Enteric-coated medications are supposed to pass intact through the gastric environment and to release the drug content into the small intestine or the colon.Before dissolution of the enteric coating,they ma... BACKGROUND Enteric-coated medications are supposed to pass intact through the gastric environment and to release the drug content into the small intestine or the colon.Before dissolution of the enteric coating,they may appear hyperdense on computed tomography(CT).Unfortunately,few reports have been published on this topic so far.In this case report,the hyperdense appearance on contrastenhanced CT of an enteric-coated mesalamine tablet was initially misinterpreted as a jejunal gastrointestinal stromal tumor(GIST).CASE SUMMARY An asymptomatic 81-year-old male patient,who had undergone laparoscopic right nephrectomy four years earlier for stage 1 renal carcinoma,was diagnosed with a jejunal GIST at the 4-year follow-up thoraco-abdominal CT scan.He was referred to our hub hospital for gastroenterological evaluation,and subsequently underwent 18-fluorodeoxyglucose positron emission tomography,abdominal magnetic resonance imaging,and video capsule endoscopy.None of these examinations detected any lesion of the small intestine.After reviewing all the CT images in a multidisciplinary setting,the panel estimated that the hyperdense jejunal image was consistent with a tablet rather than a GIST.The tablet was an 800 mg delayed-release enteric-coated oral mesalamine tablet(Asacol®),which had been prescribed for non-specific colitis,while not informing the hospital physicians.CONCLUSION Delayed-release oral mesalamine(Asacol®),like other enteric-coated medications,can appear as a hyperdense image on a CT scan,mimicking a small intestinal GIST.Therefore,adetailed knowledge of the patients’medications and a multidisciplinary review of the images areessential. 展开更多
关键词 MESALAMINE enteric-coating Asacol tablet Gastrointestinal stromal tumor Case report
下载PDF
胸腺肽防治儿童反复呼吸道感染临床疗效观察 被引量:2
5
作者 凤欣玲 《中国妇幼健康研究》 2007年第4期339-340,共2页
目的 探讨迪赛胸腺肽肠溶片防治儿童反复呼吸道感染的临床疗效.方法 对我院2003年9月~2006年9月在幼儿园确诊有反复呼吸道感染病史的98名儿童,年龄3~5岁,征得家长同意随机抽取50例作为观察组,其余48例为对照组,观察组在常规治疗的基... 目的 探讨迪赛胸腺肽肠溶片防治儿童反复呼吸道感染的临床疗效.方法 对我院2003年9月~2006年9月在幼儿园确诊有反复呼吸道感染病史的98名儿童,年龄3~5岁,征得家长同意随机抽取50例作为观察组,其余48例为对照组,观察组在常规治疗的基础上加服"迪赛胸腺肽肠溶片",5mg,每时日1次,3个月为1个疗程.对照组采用常规治疗.以上幼儿均按体弱儿进行登记、管理、每月随访,每半年评价1次,连续观察1年以上.结果 观察组总有效率明显高于对照组,分别为92.0%和66.7%(P<0.01),差异有显著性.观察组病情得到控制人数及控制率明显高于对照组,分别为25人(50.0%)和10人(20.8%),P<0.01,差异有显著性意义.结论 迪赛胸腺肽肠溶片防治儿童反复呼吸道感染,疗效显著,未发现明显不良反应,易被儿童接受,值得推广使用. 展开更多
关键词 胸腺肽肠溶片 儿童 反复呼吸道感染 疗效
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部